Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (119)	4/6/2001 1:06:58 PM
From: Jim Oravetz	Read Replies (1) of 138

Hollis-Eden Pharmaceuticals Inc (HEPH: Nasdaq) was the second largest percentage loser for the week, plunging (-27%) to close at $2.78. The company did not release any news during the period, however, rival Targeted Genetics Corp (TGEN: Nasdaq) announced on Friday that an animal trial of its experimental vaccine against the monkey form of the HIV virus prompted a strong response from immune system cells that kill foreign invaders. Hollis-Eden Pharmaceuticals is currently testing HIV vaccine products in humans. biospace.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next